Computational modeling approaches to studying the dynamics of oncolytic viruses.

Oncolytic viruses specifically infect cancer cells, replicate in them, kill them, and spread to further tumor cells. They represent a targeted treatment approach that is promising in principle, but consistent success has yet to be observed. Mathematical models can play an important role in analyzing the dynamics between oncolytic viruses and a growing tumor cell population, providing insights that can be useful for the further development of this therapy approach. This article reviews different mathematical modeling approaches ranging from ordinary differential equations to spatially explicit agent-based models. Problems of model robustness are discussed and so are some clinically important insight derived from the models.

[1]  Wilson Mok,et al.  Mathematical Modeling of Herpes Simplex Virus Distribution in Solid Tumors: Implications for Cancer Gene Therapy , 2009, Clinical Cancer Research.

[2]  Dominik Wodarz,et al.  Gene therapy for killing p53-negative cancer cells: use of replicating versus nonreplicating agents. , 2003, Human gene therapy.

[3]  Dominik Wodarz,et al.  Model-driven approaches for in vitro combination therapy using ONYX-015 replicating oncolytic adenovirus. , 2007, Journal of theoretical biology.

[4]  Natalia L. Komarova,et al.  Complex Spatial Dynamics of Oncolytic Viruses In Vitro: Mathematical and Experimental Approaches , 2012, PLoS Comput. Biol..

[5]  Frank McCormick,et al.  Future prospects for oncolytic therapy , 2005, Oncogene.

[6]  J. Bell,et al.  Getting oncolytic virus therapies off the ground. , 2003, Cancer cell.

[7]  M. Vähä-Koskela,et al.  Oncolytic viruses in cancer therapy , 2007, Cancer Letters.

[8]  Dominik Wodarz,et al.  Use of oncolytic viruses for the eradication of drug-resistant cancer cells , 2009, Journal of The Royal Society Interface.

[9]  Ken Garber,et al.  China approves world's first oncolytic virus therapy for cancer treatment. , 2006, Journal of the National Cancer Institute.

[10]  Zeljko Bajzer,et al.  Mathematical modeling of cancer radiovirotherapy. , 2006, Mathematical biosciences.

[11]  Zeljko Bajzer,et al.  Modeling of cancer virotherapy with recombinant measles viruses. , 2008, Journal of theoretical biology.

[12]  R. Martuza,et al.  Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. , 1999, Neoplasia.

[13]  Mick G. Roberts,et al.  Modeling Strategies for Containing an Invading Infection , 2006 .

[14]  Eugene V Koonin,et al.  Mathematical modeling of tumor therapy with oncolytic viruses: Regimes with complete tumor elimination within the framework of deterministic models , 2006, Biology Direct.

[15]  Douglas A. Lauffenburger,et al.  A Dynamical Systems Model for Combinatorial Cancer Therapy Enhances Oncolytic Adenovirus Efficacy by MEK-Inhibition , 2011, PLoS Comput. Biol..

[16]  Jianjun Paul Tian,et al.  Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity. , 2006, Cancer research.

[17]  D. Kirn,et al.  Replicating viruses as selective cancer therapeutics. , 1996, Molecular medicine today.

[18]  Eugene V Koonin,et al.  Mathematical modeling of tumor therapy with oncolytic viruses: effects of parametric heterogeneity on cell dynamics , 2006, Biology Direct.

[19]  Lawrence M Wein,et al.  Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. , 2003, Cancer research.

[20]  B. Fang,et al.  Oncolytic virotherapy for cancer treatment: challenges and solutions , 2005, The journal of gene medicine.

[21]  Michael P. Hassell,et al.  The Spatial and Temporal Dynamics of Host-Parasitoid Interactions , 2000 .

[22]  A. J. Hall.  Infectious diseases of humans: R. M. Anderson & R. M. May. Oxford etc.: Oxford University Press, 1991. viii + 757 pp. Price £50. ISBN 0-19-854599-1 , 1992 .

[23]  William G. Wilson,et al.  Mobility versus density-limited predator-prey dynamics on different spatial scales , 1991, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[24]  Ignacio A. Rodriguez-Brenes,et al.  Evolutionary dynamics of feedback escape and the development of stem-cell–driven cancers , 2011, Proceedings of the National Academy of Sciences.

[25]  F. McCormick,et al.  Cancer Specific Viruses and the Development of ONYX-015 , 2003, Cancer biology & therapy.

[26]  M. L. Martins,et al.  A multiscale mathematical model for oncolytic virotherapy. , 2009, Cancer research.

[27]  Hyunsuk Shim,et al.  Cancer scene investigation: how a cold virus became a tumor killer. , 2005, Future oncology.

[28]  S. Levin,et al.  OSCILLATORY DYNAMICS AND SPATIAL SCALE: THE ROLE OF NOISE AND UNRESOLVED PATTERN , 2001 .

[29]  J. Bell,et al.  Oncolytic viruses: what's next? , 2007, Current cancer drug targets.

[30]  D. Wodarz,et al.  Viruses as antitumor weapons: defining conditions for tumor remission. , 2001, Cancer research.

[31]  Z Bajzer,et al.  Dynamics of multiple myeloma tumor therapy with a recombinant measles virus , 2009, Cancer Gene Therapy.

[32]  Dominik Wodarz,et al.  ODE models for oncolytic virus dynamics. , 2010, Journal of theoretical biology.

[33]  J. Nemunaitis,et al.  Clinical development directions in oncolytic viral therapy , 2011, Cancer Gene Therapy.

[34]  J. Bell,et al.  Recent progress in the battle between oncolytic viruses and tumours , 2005, Nature Reviews Cancer.

[35]  M. Roberts,et al.  Naturally oncolytic viruses. , 2006, Current opinion in molecular therapeutics.

[36]  Rob C Hoeben,et al.  Non‐human viruses developed as therapeutic agent for use in humans , 2011, Reviews in medical virology.

[37]  J. Kaplan,et al.  Adenovirus-based cancer gene therapy. , 2005, Current gene therapy.

[38]  M. Nowak,et al.  Virus dynamics: Mathematical principles of immunology and virology , 2001 .

[39]  D M Coen,et al.  Experimental therapy of human glioma by means of a genetically engineered virus mutant , 1991, Science.

[40]  D. Kirn,et al.  From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. , 2007, Current cancer drug targets.

[41]  C. O'Shea,et al.  Viruses – seeking and destroying the tumor program , 2005, Oncogene.

[42]  Jung-Han Kimn,et al.  Optimization of Virotherapy for Cancer , 2010, Bulletin of mathematical biology.

[43]  Akira Sasaki,et al.  Pathogen invasion and host extinction in lattice structured populations , 1994, Journal of mathematical biology.

[44]  Dominik Wodarz,et al.  Towards Predictive Computational Models of Oncolytic Virus Therapy: Basis for Experimental Validation and Model Selection , 2009, PloS one.

[45]  S. Russell,et al.  History of oncolytic viruses: genesis to genetic engineering. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[46]  Cheng-Ta Yang,et al.  ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients. , 2000, Cancer research.

[47]  Nicholas R. Lemoine,et al.  Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles , 2010, Viruses.

[48]  Jorge M Pacheco,et al.  In silico evolutionary dynamics of tumour virotherapy. , 2010, Integrative biology : quantitative biosciences from nano to macro.